Watch this video to learn about biomarker assays in immuno-oncology drug development.

Watch this video to learn about the Role of a CRO in all phases of immuno-oncology drug development.

Watch this introduction video to learn about the Role of a CRO in Immuno-Oncology video series.

Key Learning Objectives: ? Introduce translational novel biomarkers to bridge nonclinical studies and human patients ? Provide an overview of successful translational biomarkers ? Provide insight into evaluation of nonclinical urine biomarker data ? Discuss translational biomarkers in clinical trials for recent renal-related diseases/mechanisms

Do you face the challenge of recruiting and retaining rare disease patients for orphan drug clinical trials? Now, discover how you can boost participation, enhance outcomes and speed drug development in this competitive market. Join Dr.

Key Learning Objectives ? Understand the regulatory environment and legal framework of the evaluation of abuse potential of CNS-active compounds under development. ? Recognize the critical steps defining the regulatory strategy of the assessment of abuse potential of CNS-active compounds in general, and in particular of analgesics. ? Identify abuse potenti

All small molecules with systemic bioavailability must conduct a study to assess that drug's proarrhythmic liability during clinical development, usually before Phase III. Updated guidance from the International Conference on Harmonisation (ICH) now allows for specific Phase I data as a reasonable substitute for a Thorough-QT (TQT) dedicated trial.

Sponsors running clinical research studies face enormous pressures today. From complex study designs, industry cost constraints, new geographical locations and significant technological advancements, there are many challenges to address.

Today's shift from organ-based symptom relief to mechanism-based treatment can be effective in treating multiple inflammatory conditions, but many factors must be considered to translate inflammation from the bench to the clinic.